Get started
Author

Julie Lasvergnas

Adoptive cell therapies in thoracic malignancies
2022 · Julie Lasvergnas, Marie Naigeon, et al. · Cancer Immunology Immunotherapy · 12
PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors
2023 · Julie Lasvergnas, Vincent Fallet, et al. · Respiratory Medicine and Research · 6
Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2025 · Jean-Baptiste Assié, Clément Meiller, et al. · Cancer Research · 4
Prediction of survival and outcomes with depth of response at 6 months in metastatic non-small-cell lung cancer patients treated with chemotherapy and immunotherapy combination: SPORE trial
2026 · F. Moinard-Butot, J.-B. Barbe-Richaud, et al. · ESMO Open · 2
PDF
Recurrence as a small cell lung cancer transformation in a resected stage IIIA EGFR-mutated non-small cell lung cancer treated with adjuvant osimertinib: a case report
2025 · Julie Lasvergnas, Isabelle Monnet, et al. · Translational Lung Cancer Research · 2
Lung cancer in recurrent respiratory papillomatosis: data from the Papilloma-Lung study
2026 · Jeremy Slomka, Thomas Maitre, et al. · European Respiratory Journal
Impact of Immune Checkpoint Inhibitor-Combined Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer With Brain Metastases
2026 · Amira Aliouat, Agathe Chareire, et al. · Clinical Lung Cancer
PDF
Supplementary Table 5 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
Supplementary Figure S21 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
Supplementary Figure S19 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
PDF
Supplementary Figure S20 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
PDF
Supplementary Figure S23 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
Supplementary Figure S3 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
PDF
Supplementary Table 3 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
Supplementary Figure S15 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
PDF
Supplementary Figure S22 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
PDF
Supplementary Figure S1 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
PDF
Supplementary Figure S9 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
PDF
Supplementary Figure S17 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
PDF
Supplementary Figure S18 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
PDF
Supplementary Figure S4 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
PDF
Supplementary Table 7 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
Supplementary Figure S14 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
PDF
Supplementary Figure S2 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
PDF
Supplementary Table 4 from Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma
2026 · Jean-Baptiste Assié, Clément Meiller, et al.
Works count: 45
Citation count: 26
H-index: 3
I10-index: 1
Year
Topic
Type